Cargando…

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Xin, Lv, Jingwen, Zhu, Wei, Tian, Chao, Li, Jingfeng, Liu, Jiajia, Zhou, Hua, Sun, Chunyang, Hu, Zongfeng, Li, Xiaopeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607272/ https://www.ncbi.nlm.nih.gov/pubmed/34808461 http://dx.doi.org/10.1016/j.tranon.2021.101287

Ejemplares similares

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
por: Li, Xiaofei, et al.
Publicado: (2022)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo
por: Zhang, Ju-Feng, et al.
Publicado: (2010)

Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus
por: Hong, Soon-Oh, et al.
Publicado: (2023)

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
por: Fallon, Jonathan K., et al.
Publicado: (2017)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
por: Kangas, Chase, et al.
Publicado: (2021)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017)

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
por: Tang, Guijin, et al.
Publicado: (2023)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
por: Robilotti, Elizabeth, et al.
Publicado: (2023)

Armed oncolytic viruses: A kick-start for anti-tumor immunity
por: de Graaf, J.F., et al.
Publicado: (2018)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Oncolytic adenovirus H101 ameliorate the efficacy of anti‐PD‐1 monotherapy in colorectal cancer
por: Huang, Lili, et al.
Publicado: (2022)

Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host’s Innate Antiviral Immunity to Attack Tumor Cells
por: Fu, Xinping, et al.
Publicado: (2020)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

Dual anti-HSV and anti-HIV activity of the lantibiotic Labyrinthopeptin A1
por: Férir, Geoffrey, et al.
Publicado: (2014)

Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
por: Monie, Dileep D., et al.
Publicado: (2021)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021)

Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy
por: Cheng, Yibin, et al.
Publicado: (2022)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model
por: Li, Pan, et al.
Publicado: (2022)

Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection
por: Salovin, Amy, et al.
Publicado: (2018)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
por: Hoang, Huy-Dung, et al.
Publicado: (2023)

Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
por: Zhang, Huan, et al.
Publicado: (2021)

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018)

The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis
por: Zeng, Yi-Fan, et al.
Publicado: (2023)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus
por: Ono, Ryosuke, et al.
Publicado: (2022)

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
por: Ring, Eric K., et al.
Publicado: (2017)

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
por: Jhawar, Sachin R, et al.
Publicado: (2023)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_08m3ap1mtfg8h15qeo8b81nofm